Oligometastatik Meme Kanserinde Bireyselleştirilmiş Tedavi Stratejileri: Cerrahi Ne Kadar Gerekli?

Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in. population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973-979. doi:10.1002/cncr.22867

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over. 20-year period:. retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742-1750. doi:10.1002/cncr.21359

Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2010;119(3):621-631. doi:10.1007/s10549-009-0630-8

Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr. 2018;2(4):pky062. doi:10.1093/jncics/pky062

Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275-292. doi:10.1016/j.cell.2011.09.024

Hellman S, Weichselbaum RR. Oligometastases.. Clin Oncol. 1995;13(1):8- 10. doi:10.1200/JCO.1995.13.1.8

Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-1495. doi:10.1016/j.annonc.2021.09.019

Imoto S, Wang K, Bi XW, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast Cancer. 2023;30(3):412-423. doi:10.1007/s12282-023-01436-7

Steenbruggen TG, Schaapveld M, Horlings HM, et al. Characterization of Oligometastatic Disease in. Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. JNCI Cancer Spectr. 2021;5(3):pkab010. Published 2021 Feb 4. doi:10.1093/jncics/pkab010

Wong Y, Raghavendra AS, Hatzis C, et al. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor. (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist. 2019;24(3):313-318. doi:10.1634/theoncologist.2018-0213

Westphal T, Gampenrieder SP, Rinnerthaler G, Greil R. Cure in metastatic breast cancer. Memo. 2018;11(3):172-179. doi:10.1007/s12254-018-0426-9

Divisi D, Barone M, Zaccagna G, et al. Surgical approach in the oligometastatic patient. Ann Transl Med. 2018;6(5):94. doi:10.21037/atm.2018.01.19

Criscitiello C, Giuliano M, Curigliano G, et al. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. Eur. Surg Oncol. 2015;41(10):1288-1292. doi:10.1016/j.ejso.2015.07.013

Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828-2834. doi:10.1245/s10434-013-2998-2

Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.. Thorac Cardiovasc Surg. 1997;113(1):37-49. doi:10.1016/s0022-5223(97)70397-0

Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases.. Clin Oncol. 1997;15(3):938-946. doi:10.1200/JCO.1997.15.3.938

Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer:. systematic review and pooled analysis.. Clin Oncol. 2008;26(7):1142-1147. doi:10.1200/JCO.2007.14.2091

Wroński M, Arbit E, Burt M, et al. Survival after surgical treatment of brain metastases from lung cancer:. follow-up study of 231 patients treated between 1976 and 1991.. Neurosurg. 1995;83(4):605-616. doi:10.3171/jns.1995.83.4.0605

Wroński M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma [published correction appears in Cancer 1998 Feb 15;82(4):following 800. Wrónski. [corrected to Wroński M]]. Cancer. 1997;80(9):1746-1754. doi:10.1002/(sici)1097-0142(19971101)80:9<1746::aid-cncr8>3.0.co;2-c

Dürr HR, Müller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res. 2002;(396):191-196. PMID: 11859243

Matsushita H, Jingu K, Umezawa R, et al. Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review. Technol Cancer Res Treat. 2018;17:1533033818803597. doi:10.1177/1533033818803597

Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.. Clin Oncol. 2016;34(25):3069-3103. doi:10.1200/JCO.2016.67.1487

Rossi V, Berchialla P, Giannarelli D, et al. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy?. Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel). 2019;11(11):1661. Published 2019 Oct 26. doi:10.3390/cancers11111661

André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.. Engl. Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904